SCHEMBL30730503

SCHEMBL30730503

Cn1ncnc1CC(=O)N1CCC(c2nc(-c3ccc(Cl)cc3F)no2)CC1

nearest known ligand 0.49

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.47
TSHR P16473 2/20 0.47
ALOX15 P16050 1/20 0.47
MAPK1 P28482 1/20 0.47
HRH3 Q9Y5N1 2/20 0.46
GRM2 Q14416 1/20 0.44
MAPT P10636 2/20 0.43
HTT P42858 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
NPSR1 Q6W5P4 2/20 0.43
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
ALDH1A1 P00352 1/20 0.43
CNR1 P21554 2/20 0.42
CNR2 P34972 2/20 0.42
KCNH2 Q12809 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL32676686 0.91 CNR1 (0.49) LMNATSHRALOX15MAPK1MAPT
SCHEMBL30730637 0.91 LMNA (0.52) LMNATSHRALOX15MAPK1HRH3
SCHEMBL30730432 0.88 CNR2 (0.51) LMNATSHRALOX15MAPK1MAPT
SCHEMBL30730598 0.86 LMNA (0.53) LMNATSHRALOX15MAPK1MAPT
SCHEMBL30730654 0.86 GRM2 (0.41) HRH3GRM2
SCHEMBL32676752 0.86 LMNA (0.55) LMNATSHRALOX15MAPK1MAPT
SCHEMBL30730617 0.85 LMNA (0.55) LMNATSHRALOX15MAPK1MAPT
SCHEMBL30730538 0.85 TSHR (0.53) LMNATSHRALOX15MAPK1MAPT
SCHEMBL30730433 0.83 LMNA (0.48) LMNATSHRALOX15MAPK1HRH3
SCHEMBL30730542 0.82 LMNA (0.68) LMNATSHRALOX15MAPK1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260048047-A1 SMALL-MOLECULE ACTIVATORS OF MYCOBACTERIUM TUBERCULOSIS ADENYLYL CYCLASE SCRIPPS RESEARCH INST (US) 2026-02-19 US claimed
WO-2024030121-A1 SMALL-MOLECULE ACTIVATORS OF MYCOBACTERIUM TUBERCULOSIS ADENYLYL CYCLASE THE SCRIPPS RESEARCH INSTITUTE (US) 2024-02-08 WO claimed
US-20260048047-A1 SMALL-MOLECULE ACTIVATORS OF MYCOBACTERIUM TUBERCULOSIS ADENYLYL CYCLASE SCRIPPS RESEARCH INST (US) 2026-02-19 US disclosed
WO-2024030121-A1 SMALL-MOLECULE ACTIVATORS OF MYCOBACTERIUM TUBERCULOSIS ADENYLYL CYCLASE THE SCRIPPS RESEARCH INSTITUTE (US) 2024-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260048047-A1 SMALL-MOLECULE ACTIVATORS OF MYCOBACTERIUM TUBERCULOSIS ADENYLYL CYCLASE FNTB, PDE7A, TBL3 LMNA 1838/4885TSHR 620/4885ALOX15 2647/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.